BioPharmSignal logoBioPharmSignal

Biotech News

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

Humacyte (HUMA)HumacyteFDA / regulatory

– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific meetings and in a recent publication – DURHAM, N.C., July 27, 2026 (GLOBE

Related news

HUMAHumacyte2026-08-24 12:00 EST

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

HUMAHumacyte2026-03-17 12:00 EST

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

View all latest news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-08-24 12:00 EST

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

HUMAHumacyte2026-08-19 12:00 EST

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

HUMAHumacyte2026-08-18 12:00 EST

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

HUMAHumacyte2026-08-12 11:00 EST

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

HUMAHumacyte2026-08-07 12:00 EST

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

Stock data

Close
0.64 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States